alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 63, Number 16 (Monday, January 26, 1998)]
[Notices]
[Page 3749]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-1722]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Board of Scientific Counselors, National Institute for 
Occupational Safety and Health: Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting:

    Name: Board of Scientific Counselors, National Institute for 
Occupational Safety and Health (BSC, NIOSH).
    Time and Date: 9 a.m.-4:30 p.m., February 11, 1998.
    Place: The Washington Court, Montpelier Room, 525 New Jersey 
Avenue, NW, Washington, DC 20001-1527.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 50 people.
    Purpose: The BSC, NIOSH is charged with providing advice to the 
Director, NIOSH on NIOSH research programs. Specifically, the Board 
shall provide guidance on the Institute's research activities 
related to developing and evaluating hypotheses, systematically 
documenting findings, and disseminating results.
    Matters to be Discussed: Agenda items include a report from the 
Director of NIOSH, research program planning, state surveillance 
activities, Workers' Family Protection Task Force, the NIOSH energy-
related research program, NIOSH Metal Working Fluids Criteria 
Document, and future activities of the Board.
    Agenda items are subject to change as priorities dictate.
    Contact Person for More Information: Bryan D. Hardin, Ph.D., 
Executive Secretary, BSC, NIOSH, Room 715-H, Hubert H. Humphrey 
Building, 200 Constitution Avenue SW, Washington, DC, 20201, 
telephone 202/205-8556, fax 202/260-4464, e-mail <a href="/cdn-cgi/l/email-protection#284a4c4019684b4c4b064f475e"><span class="__cf_email__" data-cfemail="0b696f633a4b686f68256c647d">[email protected]</span></a>.

    Dated: January 20, 1998.
Carolyn J. Russell,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 98-1722 Filed 1-23-98; 8:45 am]
BILLING CODE 4163-19-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
I 

116TH CONGRESS 

1ST SESSION H. R. 3246 

To require GAO review of certain TSA screening protocols, and for other 

purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 13, 2019 

Mr. TAYLOR (for himself and Miss RICE of New York) introduced the 

following bill; which was referred to the Committee on Homeland Security 

A BILL 

To require GAO review of certain TSA screening protocols, 

and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Traveling Parents 

5 Screening Consistency Act of 2019’’. 

6 SEC. 2. COMPTROLLER GENERAL REVIEW. 

7 Not later than one year after the date of the enact8 ment of this Act, the Comptroller General of the United 

9 States shall conduct a review of the Transportation Secu10 rity Administration’s (TSA) implementation of the Bottles 


kjohnson on DSK79L0C42 with BILLS
2 

•HR 3246 IH

1 and Breastfeeding Equipment Screening Act (Public Law 

2 114–293), as well as the effectiveness of TSA in ensuring 

3 screening protocol clarity and screening consistency relat4 ing to the screening of formula, breast milk, purified de5 ionized water for infants, and juice. Such review shall in6 clude the following: 

7 (1) Consider whether TSA effectively manages 

8 consistency of screening protocol applications for 

9 formula, breastmilk, purified deionized water for in10 fants, and juice, including the extent to which 

11 Transportation Security officers engage in screening 

12 beyond that which is prescribed through relevant 

13 policies and training. 

14 (2) Evaluate the need for TSA to update and 

15 revise procedures for such screening. 

16 (3) Assess whether TSA effectively tracks pas17 senger complaints related to such screening to mon18 itor trends and identify inconsistencies. 

19 (4) Evaluate TSA’s communications and infor20 mation sharing practices for passengers, air carriers, 

21 and airports relating to screening protocols for such 

22 screening. 

23 (5) Evaluate TSA’s policies regarding the 

24 screening of passengers with nursing products, inVerDate Sep 11 2014 02:21 Jun 18, 2019 Jkt 089200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H3246.IH H3246

kjohnson on DSK79L0C42 with BILLS
3 

•HR 3246 IH

1 cluding the extent to which such passengers are 

2 more likely to receive secondary screening. 

3 (6) Make recommendations for improving 

4 TSA’s overall screening practices relating to such 

5 screening. 

Æ 


kjohnson on DSK79L0C42 with BILLS
You

a lifetime of healthy choices,

from bike helmets to exercise.

Simply getting the HPV vaccine at ages 11 or 12 can help 

protect your child against certain cancers later in life.

Ask your child’s doctor or nurse about the HPV vaccine.

www.cdc.gov/HPV

JANUARY 2020
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr., Chief Justice

Michael F. Cavanagh

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano, Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 May 27, 2014

t0519

Order 

Clerk

May 27, 2014

148385

LEROY CAUDILL,

Plaintiff-Appellant,

v SC: 148385

COA: 310714

Oakland CC: 2011-122545-NM

SHELDON MILLER LAW FIRM, LEIB AND

LEIB LAW FIRM, SHELDON MILLER,

ANDREW ROGERS, and JEFF LEIB,

Defendants-Appellees. 

_________________________________________/

On order of the Court, the application for leave to appeal the November 19, 2013 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court.
(1) Adjusting Price $26.19 CWT

(2) Base Price $24.81 CWT

(3) Change from Base Price per CWT $1.38

(4) Price change per gallon $0.12

(Line (3) divide by 11.63 gallons/cwt)

(5) Price change per half gallon $0.06

Price change per quart $0.03 

Price change per pint $0.01

Price change per 14-oz pg. $0.01

Price change per 12-oz pg. $0.01

Price change per 1/3 qt. (10-oz) $0.01

Price change per half pint $0.01

(6) Price adjustment per gallon $0.12

Price adjustment per half gallon $0.06

Price adjustment per quart $0.03

Price adjustment per pint $0.01

Price change per 14-oz pg. $0.01

Price change per 12-oz pg. $0.01

Price adjustment per 1/3 qt. (10-oz) $0.01

Price adjustment per half pint $0.01

NOTE: Numbers in brackets are negative or decreases, all others are positive or increases.

Monthly EPA Calculation for Class I Milk (Clause 52.216-9032 Alt. I)

Based on California Marketing Area Federal Milk Order #51

 Effective Date: Nov 6th, 2022
|  | (1) | The                Report fully complies with the requirements of Section 13(a) or 15(d)                of                the Securities Exchange Act of 1934;                and |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (2) | The                information contained in the Report fairly presents, in all material                respects, the financial condition and results of operations of the                Company. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                            |                                                                                                                  |                                    |
|---------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                            |                                                                                                                  |
|                       |                                                                                                             |                               |
| Date:              June 19 2007 | By:                                                                                                         | /s/ Bernard              J. Walter |
|                            |                                                                                                                       |
|                            | Bernard                J. WalterChief                Executive Officer and Principal                Financial Officer |

----
**Exhibit
      32**




**Certification
      by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as
      Adopted**


**Pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002**





Pursuant
      to 18 U. S. C. Section 1350, I, Leslie Hudson, hereby certify that, to the
      best of my knowledge, the Quarterly Report on Form 10-Q of DOV
      Pharmaceutical, Inc. for the quarter ended March 31, 2006 (the “Report”) fully
      complies with the requirements of Section 13(a) or Section 15(d) of
      the Securities Exchange Act of 1934, and that the information contained in
      the
      Report fairly presents, in all material respects, the financial condition and
      results of operations of DOV Pharmaceutical, Inc.





A
      signed
      original of this written statement required by Section 906 has been provided
      to
      DOV and will be retained by DOV and furnished to the Securities and Exchange
      Commission or its staff upon request.





/s/
                Leslie HudsonLeslie
                  Hudson
                Chief Executive Officer and President
                May
                    9, 2006




**Certification
      by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as
      Adopted**


**Pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002**





Pursuant
      to 18 U. S. C. Section 1350, I, Barbara Duncan, hereby certify that, to the
      best of my knowledge, the Quarterly Report on Form 10-Q of DOV
      Pharmaceutical, Inc. for the quarter ended March 31, 2006 (the “Report”) fully
      complies with the requirements of Section 13(a) or Section 15(d) of
      the Securities Exchange Act of 1934, and that the information contained in
      the
      Report fairly presents, in all material respects, the financial condition and
      results of operations of DOV Pharmaceutical, Inc.





A
      signed
      original of this written statement required by Section 906 has been provided
      to
      DOV and will be retained by DOV and furnished to the Securities and Exchange
      Commission or its staff upon request.





/s/
Barbara
                DuncanBarbara
                  Duncan
                Chief Financial Officer
                May 9, 2006




These
      certifications accompany this Report on Form 10-Q pursuant to
      Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the
      extent required by such Act, be deemed filed by the Company for purposes of
      Section 18 of the Securities Exchange Act of 1934, as amended. Such
      certification will not be deemed to be incorporated by reference into any filing
      under the Securities Act of 1933, as amended, or the Securities Exchange Act,
      except to the extent that the Company specifically incorporates it by
      reference.
**EXHIBIT      32.2**

**CERTIFICATION      PURSUANT TO 18 U.S.C. SECTION 1350**

**AS      ADOPTED PURSUANT TO**

**SECTION      906 OF THE SARBANES-OXLEY ACT OF 2002**

| (1) | The                Report fully complies with the requirements of Section 13(a) or 15(d)                of                the Securities Exchange Act of 1934, as amended,                and |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | The                information contained in the Report fairly presents, in all material                respects, the financial condition and results of operations of the                Company. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |                                                                                                 |                          |
|--------|------------------------------------------------------------------------------------------------------|-------------------------------|
|   |                                                                                                 | /s/                Po Nei Sze |
|   | Po                Nei Sze Chief                Financial OfficerDate:                August 14, 2007 |

----
Exhibit 10.63a


 


1st AMENDMENT TO THE LEKSELL
GAMMA KNIFE PERFEXION PURCHASED


SERVICES AGREEMENT 


 


This 1ST AMENDMENT TO THE
LEKSELL GAMMA KNIFE PERFEXION PURCHASED SERVICES AGREEMENT ("Amendment") is effective as of October 10, 2011,
by and between Jacksonville GK Equipment, LLC ("JGKE") and St. Vincent's Medical Center, Inc ("Medical
Center").


 


RECITALS


 


WHEREAS, JGKE and Medical Center entered into that certain
Leksell Gamma Knife Perfexion Purchased Services Agreement dated August 5, 2011 (the "Agreement"); and


 


WHEREAS, under Section 6 of the
Agreement, Medical Center agreed, at its cost, to prepare, construct and improve the Site and install the Equipment provided, however,
such cost would not exceed * (the "Cap"); and


 


WHEREAS, the cost to prepare, construct and improve the
Site and install the Equipment exceeded the Cap by *; and


 


WHEREAS, JGKE agrees to pay the *; and


 


WHEREAS, for both equitable and
regulatory compliance purposes the parties desire to Amend the Purchased Services Payment percentages pursuant to the existing
methodology to take into account JGKE' s contribution of the additional * to the program.


 


NOW, THEREFORE, JGKE and Medical Center agree as follows:


 


		1.	JGKE shall contribute * to the preparation, construction and improvement of the Site and installation of the Equipment.



 


		2.	Schedule 1 of the Agreement is hereby deleted and replaced with the attached Schedule 1.



 


		3.	All capitalized terms that are not specifically defined in this Amendment are defined in the Agreement.



 


IN WITNESS WHEREOF, the parties have executed this Amendment
as of the date indicated below.


 


	Jacksonville GK Equipment, LLC	 	St. Vincent’s Medical Center, Inc.
	 	 	 
	By: /s/ Ernest A. Bates, M.D.	 	By: /s/ Moody Chisholm
	Ernest A. Bates, Manager	 	President & CEO
	Date: 11/15/11	 	Date: 11/15/11


  



    	 



    	 



    

 


Schedule 1


 


The Purchased Service Payment percentage and pro-rata share
for capital expenditures are as follows:


 


	Purchased Service Payment	Pro-rata Share for
	Percentage	Capital Expenditures
	 	 
	*	Medical Center = *
	 	 
	  	JGKE = *
<TABLE> <S> <C>

<ARTICLE> 9
<LEGEND>
This  schedule  contains  summary  financial  data  extracted from the financial
statements  of  State of Franklin Bankshares, Inc. for the six months ended June
30,  2000  and  is  qualified  in  its  entirety  by reference to such financial
statements.
</LEGEND>
<MULTIPLIER> 1

<S>                                     <C>
<PERIOD-TYPE>                           6-MOS
<FISCAL-YEAR-END>                       DEC-31-2000
<PERIOD-START>                          JAN-01-2000
<PERIOD-END>                            JUN-30-2000
<CASH>                                   6,391,688
<INT-BEARING-DEPOSITS>                     212,730
<FED-FUNDS-SOLD>                         2,333,000
<TRADING-ASSETS>                                 0
<INVESTMENTS-HELD-FOR-SALE>             22,334,258
<INVESTMENTS-CARRYING>                  13,988,847
<INVESTMENTS-MARKET>                    13,212,971
<LOANS>                                125,602,523
<ALLOWANCE>                               (896,796)
<TOTAL-ASSETS>                         179,181,015
<DEPOSITS>                             142,137,939
<SHORT-TERM>                            13,960,000
<LIABILITIES-OTHER>                        578,129
<LONG-TERM>                              6,797,786
<PREFERRED-MANDATORY>                            0
<PREFERRED>                                      0
<COMMON>                                 1,465,512
<OTHER-SE>                              14,241,649
<TOTAL-LIABILITIES-AND-EQUITY>         179,181,015
<INTEREST-LOAN>                          5,115,908
<INTEREST-INVEST>                        1,263,541
<INTEREST-OTHER>                                 0
<INTEREST-TOTAL>                         6,379,449
<INTEREST-DEPOSIT>                       3,367,778
<INTEREST-EXPENSE>                       3,824,027
<INTEREST-INCOME-NET>                    2,555,422
<LOAN-LOSSES>                              125,175
<SECURITIES-GAINS>                               0
<EXPENSE-OTHER>                          1,652,766
<INCOME-PRETAX>                          1,061,084
<INCOME-PRE-EXTRAORDINARY>               1,061,084
<EXTRAORDINARY>                                  0
<CHANGES>                                        0
<NET-INCOME>                               703,431
<EPS-BASIC>                                 .540
<EPS-DILUTED>                                 .530
<YIELD-ACTUAL>                                .031
<LOANS-NON>                                      0
<LOANS-PAST>                                11,000
<LOANS-TROUBLED>                                 0
<LOANS-PROBLEM>                                  0
<ALLOWANCE-OPEN>                           810,303
<CHARGE-OFFS>                               38,682
<RECOVERIES>                                     0
<ALLOWANCE-CLOSE>                          896,796
<ALLOWANCE-DOMESTIC>                       896,796
<ALLOWANCE-FOREIGN>                              0
<ALLOWANCE-UNALLOCATED>                          0


</TABLE>
Exhibit 32.3




                Written Statement of the Chief Operating Officer
                          Pursuant to 18 U.S.C. ss.1350

Solely for the purposes of complying with 18 U.S.C. ss.1350, I, the undersigned
President and Chief Operating Officer of Regency Centers Corporation, the
general partner of Regency Centers, L.P. (the "Company"), hereby certify, based
on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the
quarter ended March 31, 2004 (the "Report") fully complies with the requirements
of Section 13(a) of the Securities Exchange Act of 1934 and that information
contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.



Date: May 7, 2004



/s/ Mary Lou Fiala
--------------------------
Mary Lou Fiala
Chief Operating Officer
```

[Federal Register Volume 76, Number 23 (Thursday, February 3, 2011)]
[Notices]
[Page 6118]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-2475]

-----------------------------------------------------------------------

COMMISSION ON CIVIL RIGHTS

Sunshine Act Notice; Amended

AGENCY: United States Commission on Civil Rights.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

DATE AND TIME: Friday, February 11, 2011; 9:30 a.m. EST.

PLACE:  624 Ninth Street, NW., Room 540, Washington, DC 20425.

Briefing Agenda

    This briefing is open to the public.
    Topic: Disparate Impact in School Discipline Policies.
I. Introductory Remarks by Chairman.
II. Speakers' Presentations.
III. Questions by Commissioners and Staff Director.
IV. Adjourn Briefing.

Meeting Agenda

    This meeting is open to the public.
I. Approval of Agenda
II. Welcome New Commissioners
III. Management and Operations:
     Review of transition, order of succession, continuity of 
operations.
     Review of 2011 meeting calendar.
     Staff Director's report.
IV. Program Planning: Update and discussion of projects
     Cy Pres.
     Disparate Impact in School Discipline Policies.
     Gender and the Wage Gap.
     Title IX--Sex Discrimination in Liberal Arts College 
Admissions.
     Eminent Domain Project.
     NBPP.
V. State Advisory Committee Issues:
     Consideration of Vermont SAC Chair.
     Re-chartering the Alabama SAC.
VI. Approval of Dec. 3, 2010 Meeting Minutes
VII. Announcements
VIII. Adjourn

CONTACT PERSON FOR FURTHER INFORMATION: Lenore Ostrowsky, Acting Chief, 
Public Affairs Unit, (202) 376-8591. TDD: (202) 376-8116.
    Persons with a disability requiring special services, such as an 
interpreter for the hearing impaired, should contact Pamela Dunston at 
least seven days prior to the meeting at 202-376-8105. TDD: (202) 376-
8116.

    Dated: February 1, 2011.
Christopher Byrnes,
Delegated the Authority of the Staff Director.
[FR Doc. 2011-2475 Filed 2-1-11; 4:15 pm]
BILLING CODE 6335-01-P
```
Redirect for Foreign Language Terms

Similar content can be found at the following URL. Please take a moment to update 

your bookmark:

https://www.cdc.gov/vaccines/pubs/pinkbook/appendix/appdx-b.html
What Vaccines to Expect When You’re Expecting

Information for pregnant women

The CDC wants you to know that vaccines are an important part of a healthy pregnancy. 

Certain diseases can be very serious for you and your developing baby during your 

pregnancy. Getting vaccines during your pregnancy can help protect you both and 

provide your newborn with some early disease protection. 

Pregnant women should get:

z Flu vaccine

Whooping cough vaccine 

(also called Tdap) 

Your ob-gyn, midwife, or other healthcare professional may recommend other vaccines 

either before, during, or after your pregnancy. Talk to your healthcare professional about 

including vaccines as part of a healthy pregnancy. 

You can find more information at www.cdc.gov/vaccines/pregnancy

CS HCVG15-MAT-103 09/27/2016
(1) Adjusting Price

Base Skim Milk Price for Class I $7.79 CWT 0.965 $7.5174

Advanced Butterfat Pricing Factor $2.0749 LB 3.5 $7.2622

Class I Price $14.7795

(2) Base Price

Base Skim Milk Price for Class I $8.78 CWT 0.965 $8.4727

Advanced Butterfat Pricing Factor $2.3223 LB 3.5 $8.1281

Class I Price $16.6008

(3) Change from Base Price per CWT ($1.8213)

(4) Price change per gallon ($0.1566)

(Line (3) divide by 11.63 gallons/cwt)

(5) Price change per half gallon ($0.0783)

Price change per quart ($0.0391)

Price change per pint ($0.0196)

Price change per 12-oz pg. ($0.0141)

Price change per 1/3 qt. (10-oz) ($0.0118)

Price change per half pint ($0.0098)

(6) Price adjustment per gallon ($0.16)

Price adjustment per half gallon ($0.08)

Price adjustment per quart ($0.04)

Price adjustment per pint ($0.02)

Price change per 12-oz pg. ($0.01)

Price adjustment per 1/3 qt. (10-oz) ($0.01)

Price adjustment per half pint ($0.01)

**No price adjustment is required if the price change per-gallon, in either direction,

is not equal to or greater than +/-$0.0100 (See paragraph (f)(1) of the clause). 

NOTE: Numbers in brackets are negative or decreases, all others are positives or increases. 

Monthly EPA Calculation for Class I Milk (Clause 52.216-9032)

Based on USDA Announcement of Advanced Prices and Pricing Factors

Effective Date: Nov. 6, 2016